Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986
Peer-ReviewedPubMedResearch ArticleCited 1×TheranosticClinical nuclear medicine · 2026

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Perrone E, Shaheen S, Kunz PL, Henri HC, Baum RP.

Abstract

A 78-year-old man with neuroendocrine neoplasm (NEN) G2 originating from a presacral tailgut cyst was previously treated with surgery, lanreotide and [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). Due to recurrence, confirmed by [ 68 Ga]Ga-DOTA-LM3 PET/CT, which showed local, hepatic, lymph nodal, soft tissue, and cardiac disease, he received 1 cycle of PRRT with somatostatin receptor (SSTR)-antagonist DOTA-LM3 labeled with alpha-emitting Actinium-225. Due to rising levels of bilirubin 2 months after therapy, an endoscopic retrograde cholangiopancreatography diagnosed bile duct stenosis and gastric adenocarcinoma (cause of death). Autopsy findings did not reveal any residual NEN, indicating complete remission after one cycle of alpha-PRRT.

Related in the same topics